John Horton1. 1. Interdisciplinary Oncology Program at the University of South Florida, Tampa, USA. horton@moffitt.usf.edu
Abstract
BACKGROUND: Overexpression of the epidermal growth factor 2 HER2 in breast cancer tissue is associated with shorter survival. Trastuzumab, a monoclonal antibody against HER2, can induce tumor responses when given alone and enhances the effectiveness of several chemotherapeutic agents. METHODS: The recent clinical data on outcomes regarding testing for HER2 overexpression and the tolerance, toxicity, and antitumor effects of trastuzumab are reviewed. RESULTS: Trastuzumab use is indicated either alone or with chemotherapy only in patients with IHC 3+ or FISH+ test results and survival is prolonged in patients with metastatic disease. Cardiac toxicity differs from anthracycline cardiac toxicity and is often reversible. CONCLUSIONS: The safety and efficacy profile of trastuzumab in patients with metastatic disease has led to large-scale testing of addition of the intervention in the adjuvant setting.
BACKGROUND: Overexpression of the epidermal growth factor 2 HER2 in breast cancer tissue is associated with shorter survival. Trastuzumab, a monoclonal antibody against HER2, can induce tumor responses when given alone and enhances the effectiveness of several chemotherapeutic agents. METHODS: The recent clinical data on outcomes regarding testing for HER2 overexpression and the tolerance, toxicity, and antitumor effects of trastuzumab are reviewed. RESULTS:Trastuzumab use is indicated either alone or with chemotherapy only in patients with IHC 3+ or FISH+ test results and survival is prolonged in patients with metastatic disease. Cardiac toxicity differs from anthracyclinecardiac toxicity and is often reversible. CONCLUSIONS: The safety and efficacy profile of trastuzumab in patients with metastatic disease has led to large-scale testing of addition of the intervention in the adjuvant setting.
Authors: Valeriy Domenyuk; Zoran Gatalica; Radhika Santhanam; Xixi Wei; Adam Stark; Patrick Kennedy; Brandon Toussaint; Symon Levenberg; Jie Wang; Nianqing Xiao; Richard Greil; Gabriel Rinnerthaler; Simon P Gampenrieder; Amy B Heimberger; Donald A Berry; Anna Barker; John Quackenbush; John L Marshall; George Poste; Jeffrey L Vacirca; Gregory A Vidal; Lee S Schwartzberg; David D Halbert; Andreas Voss; Daniel Magee; Mark R Miglarese; Michael Famulok; Günter Mayer; David Spetzler Journal: Nat Commun Date: 2018-03-23 Impact factor: 14.919